Vancouver, British Columbia, November 18, 2021 (Globe Newswire) – Else Nutrition Holdings Inc. (TSXV: BABY) (OTCQX: BABYF) (FSE: 0YL) (The “a company“or”else“), to announce that it has received conditional approval to list its common stock and warrants on the Toronto Stock Exchange (“TSX“).
Final approval of the TSX listing is subject to the company’s fulfillment of certain customary conditions for TSX on or before January 20, 2022. Upon receiving final approval from TSX, Else intends to issue a press release confirming the date of its common stock and the warrants will begin trading on the TSX. At that time, Else’s ordinary shares and warrants will be simultaneously removed from the TSX Venture exchange. The symbol for common stock trading and company warrants in TSX will remain unchanged as “BABY”, “BABY.WT” and BABY.WT.A”.
“This is a significant achievement for the company. We believe that graduating to TSX, one of the major exchanges for publicly traded companies, will broaden our reach among institutional investors and improve our access to capital markets.” Hamutil Yitzhak, CEO and co-founder of Else Nutrition commented. “Another is at an exciting point in its growth and we are excited about our rise to TSX and look forward to sharing our story and growth strategy with a new audience of international investors.” She added.
About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean, vegan food and nutrition products for infants, toddlers, children and adults. Its revolutionary, vegan, soy-free formula is a clean ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “Best Health and Diet Solution of 2017” award at the World Food Innovation Summit in Milan. Plant-Based Complete Nutrition for Toddlers was recently ranked as a best seller in the Infant & Toddler Formulas category on Amazon. The holding company, Else Nutrition Holdings Inc. is a publicly traded company, listed under the TSX Venture Exchange under the ticker BABY, on the US OTC Markets QX under the ticker BABYF and on the Frankfurt Stock Exchange under the symbol 0YL. Else CEOs include leaders drawn from leading infant nutrition companies. Several members of Else’s advisory board have held previous executive positions at companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition associations, and some currently serve in various positions at leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at University College of Medicine Harvard, USA, Tel Aviv University, Schneider Children’s Medical Center in Israel, Rambam Medical Center and the Technion, Israel and Brussels University Hospital, Belgium.
For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.
For more information please contact:
Ms. Hamutl Yitzhak, CEO, Co-Founder and Managing Director
ELSE Nutrition Holdings Inc.
Tel: +972 (0) 3-6445095
Mr. Sukhi Pur, Director of Else Nutrition
PO Box: 604-603-7787
US Investor Relations Contact:
Lytham Partners, LLC
Mr. Ben Shamsian
New York | Phoenix
PO Box: 646-829-9701
TSX Project Exchange
Neither TSX Venture Exchange nor the Regulatory Services Provider (as defined in the TSX Venture Exchange policies) accept responsibility for the adequacy or accuracy of this release.
Caution regarding forward-looking statements
This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are usually identified by words such as “will”, “expect” or similar expressions. The forward-looking statements contained in this press release include statements regarding the expected dates for filing the company’s financial disclosure documents. These forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors that management believes are appropriate in the circumstances. No guarantees can be given as to the correctness of the foregoing. The forward-looking statements included in this press release assume, among other things, the expectation that listing in the FSE will create additional liquidity and attract additional investors in the European market. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which only reflect management’s expectations as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.